Journal of translational medicine · 2026
Noble gases xenon and argon: from cellular signalling mechanisms to organoprotection and clinical applications.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Qian, Zhu Shifan, Wu Minghui, Sun Jiashi, Kimia Moradi, Mudiyanselage Dinayinie Ekanayake, Lee Hakjun, Ma Daqing
Аннотация
BACKGROUND: Noble gases xenon (Xe) and argon (Ar) emerge as promising therapeutic agents. Extensive studies have validated their efficacy across various models of organ injury, positioning them as novel candidates for clinical translation in critical care and perioperative medicine.
MAIN BODY: Xe and Ar exert protective effects through multiple mechanisms, including activation of hypoxia-inducible factor-1 (HIF-1) pathway, inhibition of regulated cell death pathways, such as apoptosis, necroptosis, ferroptosis, and pyroptosis, and suppression of pro-inflammatory signaling. By modulating these key signaling pathways, Xe and Ar have been shown to improve outcomes in neurological, cardiac, renal, and hepatic systems across diverse models of ischemia-reperfusion injury, traumatic brain injury, and systemic inflammation. Clinically, Xe has shown efficacy in anesthesia, neonatal neuroprotection, and cardiac arrest management. Ar, with greater availability and lower costs, holds promise for broader clinical use but remains in the early stage of translational research.
CONCLUSION: Xe and Ar represent novel biologically active gases with the potential to provide promising therapies in perioperative and clinical care medicine. Overcoming current limitations, such as a lack of standardized delivery systems and optimized dosing strategies, is key to uncovering their clinical application.
MAIN BODY: Xe and Ar exert protective effects through multiple mechanisms, including activation of hypoxia-inducible factor-1 (HIF-1) pathway, inhibition of regulated cell death pathways, such as apoptosis, necroptosis, ferroptosis, and pyroptosis, and suppression of pro-inflammatory signaling. By modulating these key signaling pathways, Xe and Ar have been shown to improve outcomes in neurological, cardiac, renal, and hepatic systems across diverse models of ischemia-reperfusion injury, traumatic brain injury, and systemic inflammation. Clinically, Xe has shown efficacy in anesthesia, neonatal neuroprotection, and cardiac arrest management. Ar, with greater availability and lower costs, holds promise for broader clinical use but remains in the early stage of translational research.
CONCLUSION: Xe and Ar represent novel biologically active gases with the potential to provide promising therapies in perioperative and clinical care medicine. Overcoming current limitations, such as a lack of standardized delivery systems and optimized dosing strategies, is key to uncovering their clinical application.